drugset / Trial / NCT04688632

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632

Phase 1 Completed 72 enrolled Theravance Biopharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blind study to characterize the effect of ampreloxetine on cardiac repolarization in healthy subjects.

Timeline

Start
2021-01-18
Primary completion
2021-03-13
Completion
2021-03-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule Oral
Subject ampreloxetine Small molecule